Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients
- 2 January 2007
- journal article
- research article
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 10 (2) , 194-201
- https://doi.org/10.1038/sj.pcan.4500934
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- EAU Guidelines on Prostate CancerEuropean Urology, 2005
- Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological AssociationInternational Journal of Urology, 2005
- A re‐assessment of the role of combined androgen blockade for advanced prostate cancerBJU International, 2004
- Alternative Antiandrogens to Treat Prostate Cancer Relapse After Initial Hormone TherapyJournal of Urology, 2004
- A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5‐year follow‐upBJU International, 2003
- Goserelin Acetate with or without Antiandrogen or Estrogen in the Treatment of Patients with Advanced Prostate Cancer: A Multicenter, Randomized, Controlled Trial in JapanJapanese Journal of Clinical Oncology, 1999
- Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trialUrology, 1997
- Prostate Specific Antigen Decreases After Withdrawal of Antiandrogen Therapy with Bicalutamide or Flutamide in Patients Receiving Combined Androgen BlockadeJournal of Urology, 1997
- Case Reports: Withdrawal Phenomenon With the Antiandrogen CasodexJournal of Urology, 1995
- Prostate-specific antigen decline after casodex withdrawal: Evidence for an antiandrogen withdrawal syndromeUrology, 1994